FDA Approves Kalbitor for Treating Potentially Life-Threatening Attacks of Hereditary Angioedema
The U.S. Food and Drug Administration approved Kalbitor (ecallantide) on Dec. 1 to treat sudden and potentially life-threatening fluid buildup that can occur in people with a rare genetic condition known as hereditary angioedema (HAE).